Christina K Cramer1, Natalie Alphonse-Sullivan2, Scott Isom3, Linda J Metheny-Barlow2, Tiffany L Cummings4, Brandi R Page5, Doris R Brown2, Arthur W Blackstock2, Ann M Peiffer6, Roy E Strowd4,7, Stephen Rapp8, Glenn J Lesser7, Edward G Shaw9, Michael D Chan2. 1. Department of Radiation Oncology, Wake Forest School of Medicine, 1 Medical Center Blvd, Winston-Salem, NC, 27157, USA. ccramer@wakehealth.edu. 2. Department of Radiation Oncology, Wake Forest School of Medicine, 1 Medical Center Blvd, Winston-Salem, NC, 27157, USA. 3. Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC, 27157, USA. 4. Department of Neurology, Wake Forest School of Medicine, Winston-Salem, NC, 27157, USA. 5. Department of Radiation Oncology, Johns Hopkins School of Medicine, Baltimore, MD, 21287, USA. 6. Department of Psychology, Mars Hill University, Mars Hill, NC, 28754, USA. 7. Department of Internal Medicine (Hematology & Oncology), Wake Forest School of Medicine, Winston-Salem, NC, 27157, USA. 8. Department of Psychiatry and Behavioral Medicine, Wake Forest School of Medicine, Winston-Salem, NC, 27157, USA. 9. Department of Internal Medicine (Gerontology and Geriatrics), Wake Forest School of Medicine, Winston-Salem, NC, 27157, USA.
Abstract
INTRODUCTION: Radiation-induced cognitive decline (RICD) is a late effect of radiotherapy (RT) occurring in 30-50% of irradiated brain tumor survivors. In preclinical models, pioglitazone prevents RICD but there are little safety data on its use in non-diabetic patients. We conducted a dose-escalation trial to determine the safety of pioglitazone taken during and after brain irradiation. METHODS: We enrolled patients > 18 years old with primary or metastatic brain tumors slated to receive at least 10 treatments of RT (≤ 3 Gy per fraction). We evaluated the safety of pioglitazone at 22.5 mg and 45 mg with a dose-escalation phase and dose-expansion phase. Pioglitazone was taken daily during RT and for 6 months after. RESULTS: 18 patients with a mean age of 54 were enrolled between 2010 and 2014. 14 patients had metastatic brain tumors and were treated with whole brain RT. Four patients had primary brain tumors and received partial brain RT and concurrent chemotherapy. No DLTs were identified. In the dose-escalation phase, there were only three instances of grade ≥ 3 toxicity: one instance of neuropathy in a patient receiving 22.5 mg, one instance of fatigue in a patient receiving 22.5 mg and one instance of dizziness in a patient receiving 45 mg. The attribution in each of these cases was considered "possible." In the dose-expansion phase, nine patients received 45 mg and there was only one grade 3 toxicity (fatigue) possibly attributable to pioglitazone. CONCLUSION: Pioglitazone was well tolerated by brain tumor patients undergoing RT. 45 mg is a safe dose to use in future efficacy trials.
INTRODUCTION: Radiation-induced cognitive decline (RICD) is a late effect of radiotherapy (RT) occurring in 30-50% of irradiated brain tumor survivors. In preclinical models, pioglitazone prevents RICD but there are little safety data on its use in non-diabeticpatients. We conducted a dose-escalation trial to determine the safety of pioglitazone taken during and after brain irradiation. METHODS: We enrolled patients > 18 years old with primary or metastatic brain tumors slated to receive at least 10 treatments of RT (≤ 3 Gy per fraction). We evaluated the safety of pioglitazone at 22.5 mg and 45 mg with a dose-escalation phase and dose-expansion phase. Pioglitazone was taken daily during RT and for 6 months after. RESULTS: 18 patients with a mean age of 54 were enrolled between 2010 and 2014. 14 patients had metastatic brain tumors and were treated with whole brain RT. Four patients had primary brain tumors and received partial brain RT and concurrent chemotherapy. No DLTs were identified. In the dose-escalation phase, there were only three instances of grade ≥ 3 toxicity: one instance of neuropathy in a patient receiving 22.5 mg, one instance of fatigue in a patient receiving 22.5 mg and one instance of dizziness in a patient receiving 45 mg. The attribution in each of these cases was considered "possible." In the dose-expansion phase, nine patients received 45 mg and there was only one grade 3 toxicity (fatigue) possibly attributable to pioglitazone. CONCLUSION:Pioglitazone was well tolerated by brain tumorpatients undergoing RT. 45 mg is a safe dose to use in future efficacy trials.
Authors: Albert Attia; Stephen R Rapp; L Doug Case; Ralph D'Agostino; Glenn Lesser; Michelle Naughton; Kevin McMullen; Robin Rosdhal; Edward G Shaw Journal: J Neurooncol Date: 2012-06-15 Impact factor: 4.130
Authors: Linda Douw; Martin Klein; Selene Saa Fagel; Josje van den Heuvel; Martin Jb Taphoorn; Neil K Aaronson; Tjeerd J Postma; W Peter Vandertop; Jacob J Mooij; Rudolf H Boerman; Guus N Beute; Jasper D Sluimer; Ben J Slotman; Jaap C Reijneveld; Jan J Heimans Journal: Lancet Neurol Date: 2009-08-07 Impact factor: 44.182
Authors: Kenneth A Jenrow; Stephen L Brown; Jianguo Liu; Andrew Kolozsvary; Karen Lapanowski; Jae Ho Kim Journal: Radiat Oncol Date: 2010-02-01 Impact factor: 3.481
Authors: Ann M Peiffer; C Marc Leyrer; Dana M Greene-Schloesser; Elaine Shing; William T Kearns; William H Hinson; Stephen B Tatter; Edward H Ip; Stephen R Rapp; Mike E Robbins; Edward G Shaw; Michael D Chan Journal: Neurology Date: 2013-02-06 Impact factor: 9.910
Authors: Christina A Meyers; Jennifer A Smith; Andrea Bezjak; Minesh P Mehta; James Liebmann; Tim Illidge; Ian Kunkler; Jean-Michel Caudrelier; Peter D Eisenberg; Jacobus Meerwaldt; Ross Siemers; Christian Carrie; Laurie E Gaspar; Walter Curran; See-Chun Phan; Richard A Miller; Markus F Renschler Journal: J Clin Oncol Date: 2004-01-01 Impact factor: 44.544
Authors: Eric L Chang; Jeffrey S Wefel; Kenneth R Hess; Pamela K Allen; Frederick F Lang; David G Kornguth; Rebecca B Arbuckle; J Michael Swint; Almon S Shiu; Moshe H Maor; Christina A Meyers Journal: Lancet Oncol Date: 2009-10-02 Impact factor: 41.316
Authors: Jerome M Butler; L Douglas Case; James Atkins; Bart Frizzell; George Sanders; Patricia Griffin; Glenn Lesser; Kevin McMullen; Richard McQuellon; Michelle Naughton; Stephen Rapp; Volker Stieber; Edward G Shaw Journal: Int J Radiat Oncol Biol Phys Date: 2007-09-14 Impact factor: 7.038
Authors: Christina K Cramer; Tiffany L Cummings; Rachel N Andrews; Roy Strowd; Stephen R Rapp; Edward G Shaw; Michael D Chan; Glenn J Lesser Journal: Curr Treat Options Oncol Date: 2019-04-08
Authors: Ludmila Gouveia-Eufrasio; Noelly Queiroz Ribeiro; Julliana Ribeiro Alves Santos; Marliete Carvalho da Costa; Elúzia Castro Peres Emídio; Gustavo José Cota de Freitas; Paulo Henrique Fonseca do Carmo; Bárbara Alves Miranda; João Carlos Maia Dornelas de Oliveira; Lívia Mara Vitorino da Silva; Victor Augusto Teixeira Leocádio; Vanessa Caroline Randi Magalhães; Indiara Penido; Leonardo Soares Pereira; Lívia Frota Rabelo; Flávio Augusto de Almeida Faria; Maria Rita Teixeira Dutra; Maíra Aspahan; Ludmila de Paula; Dirce Inês da Silva; Márcia Gregory Tavares Melo; Virginia Antunes de Andrade Zambelli; André Augusto Gomes Faraco; Isabela da Costa César; Glauciene Prado Alves; Lívia Fulgêncio da Cunha Melo; Nalu Teixeira de Aguiar Peres; Daniel Assis Santos Journal: Contemp Clin Trials Commun Date: 2021-02-10